The DOI matches its Crossref record.
Introduction to the Special Issue on: Benzodiazepine Side-Effects: From the Bench to the Clinic
Abstract
This article introduces a special issue of Current Pharmaceutical Design focusing on the various side effects of benzodiazepine medications. We argue that an increased awareness of the risk of dependence, withdrawal symptoms upon discontinuation, and cognitive side effects of the benzodiazepines has likely contributed to the decline in their prescription rate over the last two decades, as has increased availability of alternative pharmacologic and non-pharmacologic treatments for anxiety and insomnia. The present special issue consists of series of five papers covering current issues in the area of benzodiazepine side effects. These reviews cover a wide range of topics pertaining to adverse, unintended consequences of this class of pharmacologic agents including their potential for tolerance and withdrawal, their profile of associated cognitive impairments, as well as current understanding of means for minimizing these unintended effects. The reviews also cover a variety of methodologies and disciplines from laboratory-based research findings with animals, to laboratory-based studies with healthy human volunteers, to findings obtained in the clinic with anxious patients. All reviews are timely contributions, covering highly relevant topics for consideration of benzodiazepine side effects at present. The papers presented herein should serve to stimulate future research that may ultimately help improve the quality of life of those patients living with debilitating anxiety-related conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TCM has also been associated with the tapering of other BZD such as clonazepam and lorazepam [38,39].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [38]
Citations
Cites
Still being checked.
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“TCM has also been associated with the tapering of other BZD such as clonazepam and lorazepam [38,39].”
BackgroundGABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery?
Whiting, P. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02703-x · Cited by 326
Awad, R., Levac, D., Cybulska, P., Merali, Z., Trudeau, V. L., & Arnason, J. T. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y07-083 · Cited by 167
Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats
Murphy, K., Kubin, Z. J., Shepherd, J. N., & Ettinger, R. H. (2010) · Phytomedicine · doi:10.1016/j.phymed.2009.10.020 · Cited by 158
Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze
Drapier, D., Bentué‐Ferrer, D., Laviolle, B., Millet, B., Allain, H., Bourin, M., & Reymann, J. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.10.002 · Cited by 123
Metadata
- Authors
- Stewart, S., & Westra, H.
- Affiliations
- Dalhousie University (CA)
- Corresponding author
- Westra, H.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2002-01-01
- Volume
- 8
- Issue
- 1
- Pages
- 1-3
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2035305597
- Cited by
- 48
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 5 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 3 · 2012: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- benzodiazepines, adverse drug reactions, benzodiazepine dependence, withdrawal symptoms, cognitive impairment, tolerance (pharmacology and immunology), anxiety disorders, insomnia, prescribing trends
- MeSH terms
- Animals, Benzodiazepines, Cognition, Humans, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Introduction to the Special Issue on: Benzodiazepine Side-Effects: From the Bench to the Clinic. https://app.cochat.ai/papers/10.2174/1381612023396708
- The paper
- Stewart, S., & Westra, H. (2002). Introduction to the Special Issue on: Benzodiazepine Side-Effects: From the Bench to the Clinic. Current Pharmaceutical Design. https://doi.org/10.2174/1381612023396708
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.